These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23584584)

  • 21. Respiratory syncytial virus: concerns and control.
    McCarthy CA; Hall CB
    Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
    [No Abstract]   [Full Text] [Related]  

  • 22. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus bronchiolitis.
    Leung AK; Kellner JD; Davies HD
    J Natl Med Assoc; 2005 Dec; 97(12):1708-13. PubMed ID: 16396064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia.
    Santos RP; Chao J; Nepo AG; Butt S; Stellrecht KA; Pearce JM; Lepow ML
    Pediatrics; 2012 Dec; 130(6):e1695-9. PubMed ID: 23147965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
    Hussman JM; Li A; Paes B; Lanctôt KL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
    Hiatt A; Bohorova N; Bohorov O; Goodman C; Kim D; Pauly MH; Velasco J; Whaley KJ; Piedra PA; Gilbert BE; Zeitlin L
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5992-7. PubMed ID: 24711420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Respiratory syncytial virus infection in adults].
    Murris-Espin M; Didier A; Carré P; Léophonte P
    Rev Mal Respir; 1995; 12(4):397-9. PubMed ID: 7481058
    [No Abstract]   [Full Text] [Related]  

  • 30. Respiratory syncytial virus (RSV) as a common cause of respiratory illness in children younger than 5 years.
    Poehling KA; Hickson GB
    Ambul Pediatr; 2003; 3(6):342-4. PubMed ID: 14616052
    [No Abstract]   [Full Text] [Related]  

  • 31. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H; Pfarr DS; Tang Y; An LL; Patel NK; Watkins JD; Huse WD; Kiener PA; Young JF
    J Mol Biol; 2005 Jul; 350(1):126-44. PubMed ID: 15907931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM).
    Kelly G; Laxton C; Garelnabi M; Alton B; Addan F; Catchpole A; Thomas E; Borley D; Dee K; Boyers A; Bringas E; Noulin N; Lambkin-Williams R; Murray EJ
    J Virol Methods; 2015 Nov; 224():83-90. PubMed ID: 26335961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H
    Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load.
    Devincenzo JP
    Pediatr Res; 2004 Dec; 56(6):914-7. PubMed ID: 15470202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Palivizumab for respiratory syncytial virus disease].
    Carrera G; D'alterio R; Leone G; Zambetti C
    Minerva Pediatr; 2013 Oct; 65(5):505-12. PubMed ID: 24056377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two new rapid antigen detection assays for respiratory syncytial virus with another assay and shell vial culture.
    Zheng X; Quianzon S; Mu Y; Katz BZ
    J Clin Virol; 2004 Oct; 31(2):130-3. PubMed ID: 15364269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of UPlink-RSV: prototype rapid antigen test for detection of respiratory syncytial virus infection.
    Mokkapati VK; Sam Niedbala R; Kardos K; Perez RJ; Guo M; Tanke HJ; Corstjens PL
    Ann N Y Acad Sci; 2007 Mar; 1098():476-85. PubMed ID: 17435154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A thin layer-based amperometric enzyme immunoassay for the rapid and sensitive diagnosis of respiratory syncytial virus infections.
    Rochelet M; Solanas S; Grossiord C; Maréchal P; Résa C; Vienney F; Barranger C; Joannes M
    Talanta; 2012 Oct; 100():139-44. PubMed ID: 23141321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.